<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Virus Res</journal-id><journal-id journal-id-type="iso-abbrev">Virus Res</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Virus Research</journal-title></journal-title-group><issn pub-type="ppub">0168-1702</issn><issn pub-type="epub">1872-7492</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8127526</article-id><article-id pub-id-type="pmcid-ver">PMC8127526.1</article-id><article-id pub-id-type="pmcaid">8127526</article-id><article-id pub-id-type="pmcaiid">8127526</article-id><article-id pub-id-type="pmid">34015363</article-id><article-id pub-id-type="doi">10.1016/j.virusres.2021.198454</article-id><article-id pub-id-type="pii">S0168-1702(21)00161-1</article-id><article-id pub-id-type="publisher-id">198454</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The COVID-19 vaccine development: A pandemic paradigm</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name name-style="western"><surname>Carneiro</surname><given-names initials="DC">Diego C.</given-names></name><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name name-style="western"><surname>Sousa</surname><given-names initials="JD">J&#233;ssica D.</given-names></name><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0015"><name name-style="western"><surname>Monteiro-Cunha</surname><given-names initials="JP">Joana P.</given-names></name><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005">Federal University of Bahia, Health Sciences Institute, Department of Biochemistry and Biophysics, Salvador, Bahia, Brazil</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#8270;</label>Corresponding author.</corresp><fn id="fn0005"><label>1</label><p id="npar0005">These authors equally contributed to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2021</year></pub-date><volume>301</volume><issue-id pub-id-type="pmc-issue-id">381930</issue-id><fpage>198454</fpage><lpage>198454</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2021</year></date><date date-type="rev-recd"><day>12</day><month>5</month><year>2021</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>05</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>18</day><month>05</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-27 22:25:42.010"><day>27</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>COVID-19 pandemic has resulted in millions of deaths and a social-economic crisis. A worldwide effort was made to develop efficient vaccines for this disease. A vaccine should produce immune responses with specific and neutralizing antibodies, and without harmful effects such as the antibody-dependent enhancement that may be associated with severe acute respiratory syndrome. Vaccine design involves the selection of platforms that includes viral, viral-vector, protein, nucleic acid, or trained immunity-based strategies. Its development initiates at a pre-clinical stage, followed by clinical trials when successful. Only if clinical trials show no significant evidence of safety concerns, vaccines can be manufactured, stored, and distributed to immunize the population. So far, regulatory authorities from many countries have approved nine vaccines with phase 3 results. In the current pandemic, a paradigm for the COVID-19 vaccine development has arisen, as many challenges must be overcome. Mass-production and cold-chain storage to immunize large human populations should be feasible and fast, and a combination of different vaccines may boost logistics and immunization. <italic toggle="yes">In silico</italic> trials is an emerging and innovative field that can be applied to predict and simulate immune, molecular, clinical, and epidemiological outcomes of vaccines to refine, reduce, and partially replace steps in vaccine development. Vaccine-resistant variants of SARS-CoV-2 might emerge, leading to the necessity of updates. A globally fair vaccine distribution system must prevail over vaccine nationalism for the world to return to its pre-pandemic status.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Coronavirus</kwd><kwd>Vaccine strategies</kwd><kwd>Vaccine safety</kwd><kwd>Emergency use</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Vaccine development attempts for previous coronaviruses</title><p id="par0230">The novel coronavirus, <italic toggle="yes">i.e.</italic> severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly. Coronavirus disease 2019 (COVID-19) has been the cause of millions of deaths and social and economic crises worldwide. The scientific community has been exploring all strategies to develop efficient vaccines against SARS-CoV-2, which is essential to reduce morbidity and mortality (<xref rid="bib0120" ref-type="bibr">Hodgson et al., 2020</xref>). Social distancing strategies help prevent transmission and reduce infection, but a vaccine is necessary for the population to acquire immunity against COVID-19. Attempts to develop several vaccines for &#946;-coronaviruses, closely related to SARS-CoV-2, such as SARS-CoV and MERS-CoV, were previously performed and tested in animal models (<xref rid="bib0240" ref-type="bibr">Roper and Rehm, 2009</xref>). Most vaccines protected animals from a challenge with SARS-CoV or MERS-CoV although many of them did not induce long-term immunity. In addition, vaccination resulted in complications in some cases, including lung damage and infiltration of eosinophils in a mouse model (<xref rid="bib0030" ref-type="bibr">Bolles et al., 2011</xref>; <xref rid="bib0005" ref-type="bibr">Agrawal et al., 2016</xref>). About 40&#8211;60 % of unexposed healthy individuals from the United States (n&#8201;=&#8201;20) presented SARS-CoV-2-reactive CD4&#8201;+&#8201;T cells, indicating the presence of a cross-reactivity immunity for other common coronaviruses (<xref rid="bib0110" ref-type="bibr">Grifoni et al., 2020</xref>).</p><p id="par0235">Efforts for vaccine development for SARS-CoV and MERS-CoV were made but failed, so the immune system managed to spontaneously suppress the infection in the population. Although their candidate vaccines have been submitted and are still in progress, there are no approved vaccines for these infectious agents so far, after 17 and 6 years of the original outbreaks, respectively (<xref rid="bib0070" ref-type="bibr">De Wit et al., 2016</xref>; <xref rid="bib0260" ref-type="bibr">Song et al., 2019</xref>). Therefore, the highest scientific standards are required for the effective development of a vaccine against COVID-19. Although previous experiments for SARS-CoV and MERS-CoV indicated potential harmful and adverse events due to increased immunity (Prompetchara et al., 2020), it is possible to learn from those vaccine attempts for other coronaviruses about how to move forward with a SARS-CoV-2 vaccine project.</p></sec><sec id="sec0010"><label>2</label><title>Vaccine development for COVID-19 in a pandemic paradigm</title><p id="par0240">A vaccine should produce specific and neutralizing antibodies. The goal is to expose the body to an antigen that stimulates the immune response, blocking or eliminating the virus in case of infection, without triggering COVID-19. Vaccines may cause adverse events that are harmful to the host due to unwanted immune enhancement responses, so careful and complete tests are required before the approval of a global vaccine for COVID-19 (<xref rid="bib0090" ref-type="bibr">Funk et al., 2020</xref>).</p><p id="par0245">Designing a vaccine requires a selection of antigens and platforms as well as forms of administration and regimen. While only antibodies to the spike (S) protein can neutralize and prevent infection, the inclusion of the nucleocapsid (N) or a non-structural protein as antigen can probably produce a balanced humoral and T-cell immunity. The route of administration and regimen significantly depends on the vaccine strategy. However, parenteral vaccination is regarded to induce timely IgG antibodies while the respiratory route better induces resident memory T cells (T<sub>RM</sub>) and trained immunity in the lungs (<xref rid="bib0125" ref-type="bibr">Jeyanathan et al., 2020</xref>).</p><p id="par0250">Scientists believe that COVID-19 severe symptoms may be better explained by the immunopathology of the Th2 response (<xref rid="bib0235" ref-type="bibr">Roncati et al., 2020</xref>). This immunopathology is based on the unregulated response of T cells, with an increased response of CD4&#8201;+&#8201;T cells specific to the virus, leading to allergic inflammation and an influx of eosinophils into the lungs (<xref rid="bib0280" ref-type="bibr">Tseng et al., 2012</xref>). <italic toggle="yes">In vivo</italic> studies have shown that infection by SARS-CoV after vaccination failed to control viral replication, increase of clinical symptoms, and pathology characterized by distorted Th2 responses, inflammation, and eosinophilic influx (<xref rid="bib0030" ref-type="bibr">Bolles et al., 2011</xref>; <xref rid="bib0280" ref-type="bibr">Tseng et al., 2012</xref>). It was also observed that pathological development might be linked to antibodies specifically targeted to the nucleocapsid protein (Bolles et al., 2011). However, a reduction in pathology was observed in vaccination studies with the spike protein (<xref rid="bib0280" ref-type="bibr">Tseng et al., 2012</xref>).</p><p id="par0255">The immunopathological effects associated with antibody-dependent enhancement (ADE) &#8211; a process by which viruses potentiate antibodies to aid infection to promote a severe inflammatory response &#8211; have been observed in viral infections, such as MERS and SARS, and have drawn attention to the possibility of ADE in COVID-19. ADE allows the infection of phagocytic antigen-presenting cells (APC), due to the binding of virus-bound antibodies to the Fc receptor on their surface (<xref rid="bib0255" ref-type="bibr">Smatti et al., 2018</xref>). Neutralizing antibodies targeting the receptor-binding domain (RBD) of MERS-CoV spike protein have been shown to mediate the entry of viruses into human cells expressing the Fc receptor <italic toggle="yes">in vitro</italic> (<xref rid="bib0300" ref-type="bibr">Wan et al., 2019</xref>).</p><p id="par0260">Studies on small cohorts of COVID-19 patients have shown that an increased response of neutralizing IgG antibodies and a higher titer of total antibodies were associated with a severe condition of the disease (<xref rid="bib0335" ref-type="bibr">Zhang et al., 2020a</xref>,<xref rid="bib0340" ref-type="bibr">b</xref>; <xref rid="bib0345" ref-type="bibr">Zhao et al., 2020</xref>). This could be evidence of ADE in SARS-CoV-2 infection (<xref rid="bib0040" ref-type="bibr">Cao, 2020</xref>). However, animal immunization studies have shown that the spike protein RBD from SARS-CoV-2 can induce a robust response of neutralizing antibodies, without inducing ADE (<xref rid="bib0220" ref-type="bibr">Quinlan et al., 2020</xref>). Most vaccine candidates for COVID-19 under development or approved for emergency or full use aim to induce neutralizing antibodies against the viral spike protein, preventing its binding to the human angiotensin 2 converter enzyme (ACE2) receptor to block infection (<xref rid="bib0270" ref-type="bibr">Thanh Le et al., 2020</xref>). Therefore, there are doubts about the ADE relevance in COVID-19.</p><p id="par0265">Developing a vaccine quickly requires a new paradigm. It is a time-consuming and expensive process (<xref rid="bib0100" ref-type="bibr">Gouglas et al., 2018</xref>). The use of state-of-the-art sequencing and reverse genetics can reduce the development time of conventional vaccines during epidemics. The urgency to develop a vaccine against SARS-CoV-2 comes at a moment of improvement in scientific understanding in areas that support vaccine development such as genomics and structural biology. Clinical trials during a pandemic show additional challenges. They are needed to confirm which populations remain at greatest risk when vaccines become available and to establish a globally fair vaccine distribution system (<xref rid="bib0150" ref-type="bibr">Lurie et al., 2020</xref>).</p><p id="par0270">As described by <xref rid="bib0090" ref-type="bibr">Funk et al. (2020)</xref>, vaccine development usually takes place in three stages. The pre-clinical stage consists of engaging research and development involving the selection of platform, design of targets and formulations, <italic toggle="yes">in vitro</italic> tests in cell culture, and <italic toggle="yes">in vivo</italic> tests in animals. If encouraging results are observed in the pre-clinical stage, the candidate vaccine proceeds to the clinical trials, which consists of testing on human volunteers in three phases: phase I, phase II, and phase III. These phases can be combined to expedite approval (<italic toggle="yes">e.g.</italic> phase II/III). Due to the pandemic nature of COVID-19, two phases have been carried out simultaneously.</p><p id="par0275">Only if the safety and efficacy of the vaccine are achieved in human volunteers, the logistics operation stage, the third and last one, is initiated to ensure worldwide distribution in a coordinated and interconnected manner (manufacture, storage, and distribution). The vaccines that did not get satisfactory results in clinical trials do not proceed to the third stage and are discontinued. Logistically, the vaccine should be easy to administer and preferably in a single dose in the smallest possible amount. An oral or intranasal vaccine would be ideal. The vaccine should be easy to produce, and the dose mass-production necessary to immunize large human populations should be feasible and fast. Long-term storage of the vaccine at room temperature should be a goal to facilitate transportation and storage (<xref rid="bib0090" ref-type="bibr">Funk et al., 2020</xref>).</p><p id="par0280">More than 160 vaccine candidates in preclinical and clinical stages are in development (<xref rid="bib0125" ref-type="bibr">Jeyanathan et al., 2020</xref>). Although produced for emergency use, they need to be safe and effective against SARS-CoV-2. Integrating knowledge on what we know so far about the virus, like infection cycle, viral recognition pathway, host immunity, and previous experiences of vaccine development attempts for other coronaviruses are important issues to consider in a pandemic scenario (<xref rid="bib0215" ref-type="bibr">Prompetchara et al., 2020</xref>). <xref rid="fig0005" ref-type="fig">Fig. 1</xref>
shows a flowchart with major steps from the pre-clinical stage to the final goal of vaccinating the population.<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart of the major steps before vaccines reach the population. Passing the pre-clinical stage, the vaccines undergo clinical trials from small to larger groups of people. If the vaccines render significant efficacy and safety, they can be manufactured in large scale, stored and distributed until vaccinations are complete.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="sec0015"><label>3</label><title><italic toggle="yes">In silico</italic> trials in the COVID-19 vaccine development</title><p id="par0285"><italic toggle="yes">In Silico</italic> Trials (IST) technologies are indispensable in the research and development stage to predict vaccine candidates before further validation for clinical trials (<xref rid="bib0055" ref-type="bibr">Chukwudozie et al., 2021</xref>). Bioinformatics and high-throughput omics technologies enabled the progress of vaccine research into the rational design of vaccines. Databases emerged to deal with their high volume of DNA, RNA, protein, and metabolite data (<xref rid="bib0115" ref-type="bibr">He and Xiang, 2013</xref>). Several platforms have been developed to predict T- and B- cell epitopes as vaccine targets, evaluate antigenicity and allergenicity, explore antibody structures and peptide-MHC binding (data-driven and structure-based methods), simulate antigen-antibody interactions, and select immuno-adjuvants using computational pipelines (<xref rid="bib0135" ref-type="bibr">Lafuente and Reche, 2009</xref>; <xref rid="bib0050" ref-type="bibr">Chukwudozie et al., 2020</xref>). <xref rid="bib0065" ref-type="bibr">Crooke et al. (2020)</xref> used predictive algorithms to analyze all structural, non-structural, and accessory proteins from SARS-CoV-2 and identified 41 and 6 T- and B- cell epitopes, respectively.</p><p id="par0290">In addition, bioinformatics can predict protein structures, post-translational modifications (PTMs), and aid in the design of linkers for fusion proteins. This way, it is possible to shorten the time spent on experimental research. Along with clinical and epidemiological data, these tools can speed up and decrease the costs of the experimental immunogenicity assessment of vaccines. Moreover, predicted data can be further stored in databases specific to vaccine design (<xref rid="bib0115" ref-type="bibr">He and Xiang, 2013</xref>; <xref rid="bib0020" ref-type="bibr">Bahrami et al., 2019</xref>). <xref rid="bib0165" ref-type="bibr">Mercurio et al. (2021)</xref> performed an <italic toggle="yes">in silico</italic> modeling approach to analyze structural changes in the protein S RBD favoring ACE2 binding. This method can be used to identify neutralizing antibodies or build new ones, with applications in the development of new vaccines.</p><p id="par0295">Efficiency to obtain SARS-CoV-2 genome data, supported by bioinformatics platforms, was critical to design vaccines through available technologies (<xref rid="bib0055" ref-type="bibr">Chukwudozie et al., 2021</xref>). Those technologies include reverse vaccinology, which identifies novel antigens through analysis of genomic information (<xref rid="bib0285" ref-type="bibr">Ullah et al., 2020</xref>), immunoinformatics that analyzes an organism&#8217;s immunomics to make predictions of immune responses against specific molecules, and structural vaccinology that focuses on the conformational features of the viral epitope that makes them good candidate antigens (<xref rid="bib0160" ref-type="bibr">Mar&#237;a et al., 2017</xref>).</p><p id="par0300">IST can also simplify preclinical and clinical stages that can be modeled through computational approaches for the improvement of vaccine development, which is referred to as <italic toggle="yes">in silico</italic> clinical trials (ISCT) (<xref rid="bib0200" ref-type="bibr">Pappalardo et al., 2019</xref>). Virus&#8211;host interaction, immunization modeling, vaccination schedules, assessment of vaccine safety and efficacy commonly use agent-based modeling (ABM), a model based on the simulation of the dynamics of single entities that interact with each other following simple known rules and differential equations as computational and mathematical approaches (<xref rid="bib0185" ref-type="bibr">Pappalardo et al., 2010</xref>, <xref rid="bib0190" ref-type="bibr">2015</xref>).</p><p id="par0305">ISCT has been used effectively in preclinical studies to optimize dosage administration and schedule, maintaining a prolonged immune response that effectively protects the host (<xref rid="bib0085" ref-type="bibr">Finn and Beatty, 2016</xref>; <xref rid="bib0185" ref-type="bibr">Pappalardo et al., 2010</xref>, <xref rid="bib0195" ref-type="bibr">2016</xref>). In clinical studies, modeling and simulation provide a reliable prediction of outcomes based on the data collected to increase confidence before investing in a new trial phase. <xref rid="bib0245" ref-type="bibr">Russo et al. (2020)</xref> applied a human immune system simulator with a SARS-CoV-2 disease model to predict the outcome of a candidate vaccine strategy. The vaccine presented a good agreement with experimental data.</p><p id="par0310">Computer models can be applied in the development or regulatory assessment of vaccines to reduce, refine or partially replace pre-clinical and clinical trials. These models are useful to predict the average effect of a vaccine over a population or each individual in a population to test safety and efficacy (<xref rid="bib0200" ref-type="bibr">Pappalardo et al., 2019</xref>). A computational model indicated that COVID-19 vaccines should have an efficacy of at least 70 % to prevent epidemics and 80 % to prevent completely an epidemic without prevention measures such as social distancing (<xref rid="bib0025" ref-type="bibr">Bartsch et al., 2020</xref>). <xref rid="fig0010" ref-type="fig">Fig. 2</xref>
illustrates the process of <italic toggle="yes">in silico</italic> trials applications in vaccine development.<fig id="fig0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Applications of <italic toggle="yes">in silico</italic> trials in vaccine development. Each vaccine development stage can use bioinformatics approaches to process and analyze viral molecular data by omics technologies and clinical and epidemiological data. The predicted data can be further deposited in vaccine databases that are used to refine, reduce, and partially replace steps in vaccine development.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p><p id="par0315"><italic toggle="yes">In silico</italic> analysis has been an innovative and emergent area, essential and mandatory to accelerate vaccine development, especially in a pandemic scenario, and has contributed to making the COVID-19 vaccine development the fastest so far. However, <italic toggle="yes">in silico</italic> experiments have the disadvantages of no possible exploration of new side effects or failures never observed before (<xref rid="bib0200" ref-type="bibr">Pappalardo et al., 2019</xref>). Another important challenge is the translation of experimental data to the clinical level. Advances in technology and computational modeling are helping to overcome this translational gap (<xref rid="bib0010" ref-type="bibr">An et al., 2011</xref>). Therefore, combined use of <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vivo</italic> experimentation is important as one approach compensates the limitations of the other (<xref rid="bib0045" ref-type="bibr">Carusi et al., 2012</xref>).</p></sec><sec id="sec0020"><label>4</label><title>Vaccines for COVID-19: variety of strategies</title><p id="par0320">There are at least eight types of vaccines against SARS-Cov-2: viral vaccines (attenuated or inactivated), viral vector-based vaccines (replicative or non-replicative), protein-based vaccines (proteins subunits or virus-like particles), and nucleic acid-based vaccines (DNA or RNA) (<xref rid="bib0035" ref-type="bibr">Callaway, 2020</xref>). They generally require two basic components: the antigen(s) and a signal of infection that activates the immune system. Non-viral or inactivated-virus vaccines can provide antigens but usually require adjuvants to induce the signal (<xref rid="bib0305" ref-type="bibr">Wang et al., 2020</xref>). Their advantages and disadvantages are summarized in <xref rid="tbl0005" ref-type="table">Table 1</xref>
.<table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 1</label><caption><p>Summary of the characteristics of each vaccine platform.</p></caption><alt-text id="at0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Platform</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Live-attenuated</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#8226;</label><p id="par0005">Elicit strong immune response</p></list-item><list-item id="lsti0010"><label>&#8226;</label><p id="par0010">Highly established</p></list-item><list-item id="lsti0015"><label>&#8226;</label><p id="par0015">Long-lasting protection</p></list-item><list-item id="lsti0020"><label>&#8226;</label><p id="par0020">Do not need adjuvants</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0010"><list-item id="lsti0025"><label>&#8226;</label><p id="par0025">Requires dedicated biosafety</p></list-item><list-item id="lsti0030"><label>&#8226;</label><p id="par0030">Risk of regaining virulence</p></list-item><list-item id="lsti0035"><label>&#8226;</label><p id="par0035">Causes reactogenicity</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0015"><list-item id="lsti0040"><label>&#8226;</label><p id="par0040">Elicit strong immune response</p></list-item><list-item id="lsti0045"><label>&#8226;</label><p id="par0045">Highly established</p></list-item><list-item id="lsti0050"><label>&#8226;</label><p id="par0050">Less reactogenicity than live-attenuated</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0020"><list-item id="lsti0055"><label>&#8226;</label><p id="par0055">Lower immune response than live-attenuated</p></list-item><list-item id="lsti0060"><label>&#8226;</label><p id="par0060">Needs adjuvants</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral-vectors</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0025"><list-item id="lsti0065"><label>&#8226;</label><p id="par0065">Precise immune response</p></list-item><list-item id="lsti0070"><label>&#8226;</label><p id="par0070">Safer than live-attenuated and inactivated vaccines</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0030"><list-item id="lsti0075"><label>&#8226;</label><p id="par0075">Variable immunogenicity</p></list-item><list-item id="lsti0080"><label>&#8226;</label><p id="par0080">Can be influenced by preexisting vector antibodies</p></list-item><list-item id="lsti0085"><label>&#8226;</label><p id="par0085">Risk of genomic integration</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein-based</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0035"><list-item id="lsti0090"><label>&#8226;</label><p id="par0090">No biosafety concerns</p></list-item><list-item id="lsti0095"><label>&#8226;</label><p id="par0095">Strong antibody immunogenicity</p></list-item><list-item id="lsti0100"><label>&#8226;</label><p id="par0100">Precedent of successful vaccines</p></list-item><list-item id="lsti0105"><label>&#8226;</label><p id="par0105">Can be formulated into virus-like particles</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0040"><list-item id="lsti0110"><label>&#8226;</label><p id="par0110">Needs adjuvants</p></list-item><list-item id="lsti0115"><label>&#8226;</label><p id="par0115">May not carry glycans similar to the viral proteins</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0045"><list-item id="lsti0120"><label>&#8226;</label><p id="par0120">No biosafety concerns</p></list-item><list-item id="lsti0125"><label>&#8226;</label><p id="par0125">Elicit reasonable immune response</p></list-item><list-item id="lsti0130"><label>&#8226;</label><p id="par0130">Long-term stability</p></list-item><list-item id="lsti0135"><label>&#8226;</label><p id="par0135">Can be multivalent</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0050"><list-item id="lsti0140"><label>&#8226;</label><p id="par0140">Variable immunogenicity</p></list-item><list-item id="lsti0145"><label>&#8226;</label><p id="par0145">Risk of genomic integration</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0055"><list-item id="lsti0150"><label>&#8226;</label><p id="par0150">No biosafety concerns</p></list-item><list-item id="lsti0155"><label>&#8226;</label><p id="par0155">No risk of genomic integration</p></list-item><list-item id="lsti0160"><label>&#8226;</label><p id="par0160">Elicit strong immune response</p></list-item><list-item id="lsti0165"><label>&#8226;</label><p id="par0165">Can be multivalent</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0060"><list-item id="lsti0170"><label>&#8226;</label><p id="par0170">Possible inflammatory reaction</p></list-item><list-item id="lsti0175"><label>&#8226;</label><p id="par0175">May require ultra-cold storage</p></list-item><list-item id="lsti0180"><label>&#8226;</label><p id="par0180">Require delivery by lipid nanoparticles</p></list-item></list></td></tr><tr><td align="left" colspan="1" rowspan="1">Trained immunity-based</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0065"><list-item id="lsti0185"><label>&#8226;</label><p id="par0185">Can boost the innate immune response</p></list-item><list-item id="lsti0190"><label>&#8226;</label><p id="par0190">Already available</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="lis0070"><list-item id="lsti0195"><label>&#8226;</label><p id="par0195">Efficacy and mechanisms still not well understood</p></list-item><list-item id="lsti0200"><label>&#8226;</label><p id="par0200">No induction of adaptive immunity memory</p></list-item><list-item id="lsti0205"><label>&#8226;</label><p id="par0205">Reversible and short-durable</p></list-item></list></td></tr></tbody></table></table-wrap></p><p id="par0325">The platform, adjuvant(s), form of administration, age, and pre-existing cross-reactive immunity essentially determine the safety of a vaccine. Alum and bacterial-derived proteins as well as replicating live-attenuated virus or vectored vaccines may not be safe for respiratory administration. Possible induction of ADE and high-level secretion of proinflammatory cytokines may also raise safety concerns for the COVID-19 vaccine (<xref rid="bib0225" ref-type="bibr">Rauch et al., 2018</xref>; <xref rid="bib0125" ref-type="bibr">Jeyanathan et al., 2020</xref>).</p><sec id="sec0025"><label>4.1</label><title>Viral vaccines</title><p id="par0330">Viral vaccines use the virus itself, in attenuated or inactivated form, with reduced virulence. This strategy can induce a rapid and strong immune response, but it can be dangerous for immunosuppressed people. Many existing vaccines are made this way, such as those against measles and polio, but require extensive safety testing. Attenuated viruses are conventionally passed through animals or human cells until they acquire mutations that make them less pathogenic. Inactivated viruses become less infective through exposure to chemicals, such as formaldehyde, or to heat. However, it requires the production of many live viruses (<xref rid="bib0035" ref-type="bibr">Callaway, 2020</xref>). The advantages consist of proven technology, triggering of strong immune responses, multivalence, and simple formulation that does not require adjuvant. The attenuated vaccines still have a proven history of good cost-benefit for large-scale manufacturing. The disadvantages are the requirement of dedicated biosecurity level installations, and in the case of attenuated viruses, there is a risk of virulence recovering (<xref rid="bib0090" ref-type="bibr">Funk et al., 2020</xref>).</p></sec><sec id="sec0030"><label>4.2</label><title>Viral vector-based vaccines</title><p id="par0335">Viral vector-based vaccines use a viral structure to introduce SARS-CoV-2 genes into the host. This strategy can increase immunogenicity without an adjuvant and promotes a robust cytotoxic T-cell response to eliminate virus-infected cells. In some vaccines, the vector enters the cells and manages SARS-CoV-2 protein production but cannot replicate because key genes have been disabled. In other vaccines, the vector replicates slowly, carrying SARS-CoV-2 proteins on its surface (<xref rid="bib0155" ref-type="bibr">Machhi et al., 2021</xref>). The weakened measles virus is an example of a viral vector that replicates within cells. These vaccines tend to be safe and induce a strong immune response. Existing immunity against the vector can reduce the effectiveness of the vaccine. The non-replicative viral vector, such as adenovirus, has a long history in gene therapy. An extra administration of the vaccine after an initial dose (booster shot) may be required to induce long-term immunity (<xref rid="bib0290" ref-type="bibr">Ura et al., 2014</xref>). The advantages consist of years of experience in the field of gene therapy, studying the safety and immune response, strong cellular response, and antibody production. Disadvantages include risk of chromosomal integration and oncogenesis, no possibility of used in immunocompromised individuals, pre-existence of antibodies to some vectors, potential for inflammatory adverse events, variable immunogenicity, and significant barriers for manufacturing at a large scale (<xref rid="bib0265" ref-type="bibr">Strizova et al., 2021</xref>).</p></sec><sec id="sec0035"><label>4.3</label><title>Protein-based vaccines</title><p id="par0340">In this type of vaccine, coronavirus proteins are injected directly into the body. Similarly, fragments of shells and proteins that mimic the virus structure can also be used. Most vaccines are based on viral protein subunits with a focus on the spike protein or, more precisely, the RBD. Similar vaccines against SARS-CoV protected monkeys from infection but have not been tested in humans. Those vaccines may require adjuvants, immunostimulant molecules, as well as multiple doses to work well. A vaccine based on virus-like particles or wrapped empty viruses that mimic SARS-CoV-2 structure is not infectious because they lack genetic material. These vaccines can trigger a strong immune response, but they can be difficult to manufacture (<xref rid="bib0205" ref-type="bibr">Park et al., 2021</xref>).</p></sec><sec id="sec0040"><label>4.4</label><title>Nucleic acid-based vaccines</title><p id="par0345">Here, the nucleic acid of SARS-CoV-2 is inserted into human cells, which produce copies of virus proteins that stimulate an immune response. Most of these vaccines encode the spike protein. DNA vaccines use plasmid DNA to efficiently deliver and express SARS-CoV-2 antigens to host cells. Electroporation is a delivery system that creates pores in cell membranes to increase DNA absorption. Currently, there are no DNA vaccines approved for humans. mRNA vaccines encode a SARS-CoV-2 antigen and use a delivery system, such as a liposome, to carry the mRNA molecule into host cells. The advantages of DNA and RNA-based vaccines are that they are safe and easy to develop. To produce them, only the virus genome is needed, not the complete virus. Among the disadvantages is the fact that there is no vaccine licensed with this technology so far (<xref rid="bib0075" ref-type="bibr">Delany et al., 2014</xref>; <xref rid="bib0265" ref-type="bibr">Strizova et al., 2021</xref>).</p></sec><sec id="sec0045"><label>4.5</label><title>The trained immunity-based strategy</title><p id="par0350">Innate immune responses are, after physical and chemical barriers, the line of defense against invading pathogens. Only when this line of defense is dominated by pathogens, the adaptive immune response (T and B cells) is activated. For a long time, it was believed that only adaptive immune system cells could generate immune memory and protect against recurrent infections. This property of the lymphocytes is the basis of vaccine effectiveness against specific infections. However, it has been shown that innate immune cells may also present adaptive characteristics after certain infections or vaccines; a property that is functionally like the construction of immune memory (<xref rid="bib0170" ref-type="bibr">Netea et al., 2020a</xref>).</p><p id="par0355">This process called trained immunity is the reprogramming of the innate immune system cells by external or internal primary stimulations that lead to a higher response at a second immune challenge. It is mediated by an epigenetics reprogramming instead of the genetic recombination from the adaptive immune memory, resulting in metabolic changes and higher responsiveness with long-term effects, but generally reversible and less durable. This cellular reprogramming allows rapid accessibility of transcription factors to the promoter, potentiating regions of pro-inflammatory genes after restimulation, and facilitates gene expression. Increased metabolic activity of the cell provides rapid energy supply and metabolites needed to generate a robust immune response after restimulation (<xref rid="bib0175" ref-type="bibr">Netea et al., 2020b</xref>)</p><p id="par0360">In the category of repurposed vaccines - vaccines already in use for other diseases that may protect against SARS-CoV-2 - is the vaccine based on trained immunity against <italic toggle="yes">Bacillus Calmette-Guerin (BCG)</italic>, developed in the early 1900s as a protection against tuberculosis. Public available data suggests that countries without universal BCG vaccination were more severely affected by the COVID-19 pandemic than countries with universal and established BCG vaccination policies. This vaccine has presented protection in animals by trained immunity against infections of <italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">Schistosoma mansoni</italic>, and <italic toggle="yes">Mycobacterium tuberculosis</italic> (<xref rid="bib0275" ref-type="bibr">Tribouley et al., 1978</xref>; <xref rid="bib0325" ref-type="bibr">Wout et al., 1992</xref>; <xref rid="bib0130" ref-type="bibr">Kaufmann et al., 2018</xref>).</p></sec></sec><sec id="sec0050"><label>5</label><title>Some of the major vaccines for COVID-19 approved for emergency and full use</title><p id="par0365">In Phase 3 clinical trial, the vaccine is tested on thousands of people, who are monitored to evaluate how many will be infected, compared to those who received placebo. The volunteers do not know whether they received a placebo or vaccine. These tests can determine whether the vaccine protects against coronavirus by measuring what is known as the efficacy rate. The World Health Organization (WHO) suggested that efficacy with 50 % must be a minimum criterion for any acceptable COVID-19 vaccine, and that efficacy can be evaluated against disease development, progression of mild or moderate-to-severe disease, and/or shedding/transmission (<xref rid="bib0120" ref-type="bibr">Hodgson et al., 2020</xref>). Phase 3 trials determine vaccine safety, efficacy, and protection. Early or limited approval is based on preliminary evidence that vaccines are safe and effective. Full approval occurs when the regulatory agency reviews the complete test results and the plans to manufacture a vaccine (<xref rid="bib0090" ref-type="bibr">Funk et al., 2020</xref>). <xref rid="tbl0010" ref-type="table">Table 2</xref>
shows information about the COVID-19 vaccines with phase 3 results approved by countries&#8217; regulatory authorities, according to the <xref rid="bib0060" ref-type="bibr">COVID-19 Vaccine Tracker (2021)</xref> until March 27, 2021.<table-wrap position="float" id="tbl0010" orientation="portrait"><label>Table 2</label><caption><p>Latest information on COVID-19 vaccines with approvals and phase 3 clinical trial results.</p></caption><alt-text id="at0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Developer country</th><th align="left" colspan="1" rowspan="1">Developer</th><th align="left" colspan="1" rowspan="1">Vaccine name</th><th align="left" colspan="1" rowspan="1">Strategy</th><th align="left" colspan="1" rowspan="1">Regimen</th><th align="left" colspan="1" rowspan="1">Efficacy</th><th align="left" colspan="1" rowspan="1">Storage</th><th align="left" colspan="1" rowspan="1">Countries approvals</th><th align="left" colspan="1" rowspan="1">Latest publication</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">United States and Germany</td><td align="left" colspan="1" rowspan="1">Pfizer-Biotech</td><td align="left" colspan="1" rowspan="1">BNT162b2</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1">95 %</td><td align="left" colspan="1" rowspan="1">&#8722;80 to -60&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">79 approvals (US, UK, EU, AR, AU, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0210" ref-type="bibr">Polack et al., 2020</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">United States and Germany</td><td align="left" colspan="1" rowspan="1">Janssen</td><td align="left" colspan="1" rowspan="1">Ad26.COV2.S</td><td align="left" colspan="1" rowspan="1">Ad26</td><td align="left" colspan="1" rowspan="1">One-dose</td><td align="left" colspan="1" rowspan="1">74.4 % (US), 64.7 % (LatAm), 52.0 % (ZA)</td><td align="left" colspan="1" rowspan="1">2 to 8&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">35 approvals (US, EU, CA, ZA, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0180" ref-type="bibr">Oliver et al., 2021</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">United States</td><td align="left" colspan="1" rowspan="1">Moderna</td><td align="left" colspan="1" rowspan="1">mRNA-1273</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1">94.0 %</td><td align="left" colspan="1" rowspan="1">&#8722;25 to -15&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">41 approvals (US, UK, EU, IL, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0015" ref-type="bibr">Baden et al., 2021</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">United Kingdom and Sweden</td><td align="left" colspan="1" rowspan="1">Oxford-AstraZeneca</td><td align="left" colspan="1" rowspan="1">AZD-1222</td><td align="left" colspan="1" rowspan="1">ChAdOx1</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1">70.4 %</td><td align="left" colspan="1" rowspan="1">2 to 8&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">81 approvals (UK, EU, BR, IN, MA, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0295" ref-type="bibr">Voysey et al., 2021</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Russia</td><td align="left" colspan="1" rowspan="1">Gamaleya</td><td align="left" colspan="1" rowspan="1">Sputnik-V</td><td align="left" colspan="1" rowspan="1">Ad26, Ad5</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1">91.6 %</td><td align="left" colspan="1" rowspan="1">&#8722;18&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">55 approvals (RU, AR, AE, GN, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0145" ref-type="bibr">Logunov et al., 2021</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">CanSino</td><td align="left" colspan="1" rowspan="1">Ad5-nCoV<break/>(Convidecia)</td><td align="left" colspan="1" rowspan="1">Ad5</td><td align="left" colspan="1" rowspan="1">One-dose</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NA</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NA</italic></td><td align="left" colspan="1" rowspan="1">4 approvals (CN, HU, MX, PK)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0350" ref-type="bibr">Zhu et al., 2020</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">Sinopharm</td><td align="left" colspan="1" rowspan="1">BBIBP-CorV</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NA</italic></td><td align="left" colspan="1" rowspan="1">2 to 8&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">27 approvals (BH, EG, HU, IQ, PE, CS, AE, others)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0330" ref-type="bibr">Xia et al., 2021</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">Sinovac</td><td align="left" colspan="1" rowspan="1">CoronaVac</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1">50.4 %</td><td align="left" colspan="1" rowspan="1">2 to 8&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">19 approvals (BR, CL, CN, ID, TR, others)</td><td align="left" colspan="1" rowspan="1">Zhang et al., 2021</td></tr><tr><td align="left" colspan="1" rowspan="1">India</td><td align="left" colspan="1" rowspan="1">Bharat Biotech</td><td align="left" colspan="1" rowspan="1">BBV152 (Covaxin)</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Two-dose</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NA</italic></td><td align="left" colspan="1" rowspan="1">2 to 8&#8201;&#176;C</td><td align="left" colspan="1" rowspan="1">5 approvals (IN, IR, MA, NP, ZW)</td><td align="left" colspan="1" rowspan="1"><xref rid="bib0080" ref-type="bibr">Ella et al., 2021</xref></td></tr></tbody></table><table-wrap-foot><fn id="spar0035"><p>AR: Argentina; AE: United Arab Emirates; AU: Australia; BH: Bahrain; BR: Brazil; CA: Canada; CL: Chile; CN: China; EG: Egypt; EU: European Union; GN: Guinea; HU: Hungary; ID: Indonesia; IL: Israel; IN: India; IR: Iran; IQ: Iraq; LatAm: Latin American; MA: Morocco; MA: Mauritius; MX: Mexico; NP: Nepal; PE: Peru; PK: Pakistan; RU: Russia; TR: Turkey; UK: United Kingdom; CS: Republic of Serbia; ZA: South Africa; ZW: Zimbabwe; LatAm: Latin America.</p></fn><fn id="spar0040"><p><italic toggle="yes">NA</italic>: Not available.</p></fn></table-wrap-foot></table-wrap></p><p id="par0370">It is important to consider the uncertainty of the results of vaccination that has already started. In other words, if there will be protection in the short or long term. According to <xref rid="bib0095" ref-type="bibr">Gaebler et al. (2021)</xref>, levels of antibodies against SARS-CoV-2 spike protein declined over six months following infection, which has raised concerns that immunity to the virus probably declines rapidly. However, levels of memory B cells, which are specific for making antibodies against the spike protein, remained constant. Intestine sample analyzes, after 4 months of infection, revealed that half of the participants had persistent protein or RNA markers for SARS-CoV-2, potentially providing a continued source of stimulation to the immune system.</p><p id="par0375">Mutations can help SARS-CoV-2 to escape the immune response of a subset of infected people. Researchers have identified thousands of mutations in SARS-CoV-2 samples, but the vast majority are unlikely to have an effect on viral biology (<xref rid="bib0105" ref-type="bibr">Greaney et al., 2021</xref>). Antibody responses were tested to spike protein samples and indicated that each sample carried different RBD versions. This spike protein sequence recognizes host cells and is a major target for antibodies. Out of thousands of RBD mutations tested, only a few reduced the antibodies' ability to bind tightly to the spike protein. At least one of these variants is easier transmitted than other forms of the virus currently in wide circulation (<xref rid="bib0310" ref-type="bibr">Wang et al., 2021</xref>). These findings suggest that vaccine-resistant variants might emerge, meaning that COVID-19 vaccines may need an update.</p></sec><sec id="sec0055"><label>6</label><title>COVID-19 vaccine nationalism</title><p id="par0380">According to <xref rid="bib0230" ref-type="bibr">Ritchie et al. (2021)</xref> (Our World in Data), until March 26, 62 % of the world COVID-19 vaccine doses were administered in four countries: United States, China, India, and United Kingdom (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>
A). Only the United States accounted for 41 % of the number of people fully vaccinated in the world (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>B). Those data suggest a great inequality in the global distribution of vaccines. <xref rid="fig0020" ref-type="fig">Fig. 4</xref>
shows that developed and developing countries lead on the share of the world population fully vaccinated, indicating that they are the most likely to first achieve herd immunity. According to the <xref rid="bib0320" ref-type="bibr">World Tourism Organization (2021)</xref>, Europe shared 51 % of the world's international tourist arrivals in 2019 while North America and North-East Asia shared 10 % and 12 %, respectively. In 2020, COVID-19 was responsible for a plunge of 74 % in the number of international tourist arrivals. Therefore, vaccination needs to achieve sufficient equality between all countries for the world to return to a pre-pandemic status, especially if new mutations, capable of circumventing the immunization of current vaccines, arises in the populations of countries with a long-lasting COVID-19 epidemic.<fig id="fig0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Total number vaccine single doses administered (A) and total number of people fully vaccinated (B) for COVID-19 per country. Single doses do not represent the number of people fully vaccinated as many vaccines require two-dose regimen for complete immunization.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig><fig id="fig0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>World map showing the share of the country population who achieved full vaccination. This map shows the percentage of the country population who received all required doses prescribed by the vaccines for complete immunization.</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4_lrg.jpg"/></fig></p><p id="par0385">Despite the independent race for the vaccine, the current scenario converges towards possible cooperation to implement a strategy known as heterologous prime-boost against the coronavirus in an attempt to facilitate the logistics of immunization and to increase the immune responses in the process. Most coronavirus vaccines are administered in two doses: an initial dose followed by a booster to stimulate the immune system's memory cells and amplify the immune response. Researchers in the United Kingdom propose to test the immune responses for the combination of its Oxford-AstraZeneca and Pfizer or Sputnik V vaccines. A heterologous prime-boost combination against Ebola was approved in 2020 by European regulators. Experimental HIV vaccines also rely on this strategy (<xref rid="bib0140" ref-type="bibr">Ledford, 2021</xref>). If the production of antibodies and the safety of this strategy are experimentally proven, fighting variants of the coronavirus could be a relevant alternative that could accelerate the vaccination process and reduce the impact of any interruptions in the supply chain.</p><p id="par0390">The Access to COVID-19 Tools &#8211; ACT Accelerator is an initiative of WHO with collaborators from around the world to join efforts to combat the pandemic. In an ideal scenario, the proposal was to unite the countries, aiming at the common good, focusing on the diagnosis, therapy, and vaccination for COVID-19. The vaccine pillar of ACT Accelerator is the Global Vaccine Access Instrument for COVID-19: COVAX Facility. Its purpose is to coordinate a global risk-sharing mechanism for joint acquisition, and the equitable distribution of possible vaccines of COVID-19 (<xref rid="bib0315" ref-type="bibr">WHO, 2020</xref>). However, this alliance was not established among the countries. Instead, they started an independent race for the vaccine. The WHO&#8217;s director Tedros Adhanom Ghebreyesus warned that national interests in the COVID-19 vaccine could impede global efforts and prolong the pandemic of the new coronavirus. In his words: &#8220;Sharing vaccines or sharing other tools actually helps the world to recover together. The economic recovery can be faster and the damage from COVID-19 could be less. Vaccine nationalism is not good, it will not help us. We must seize this moment to come together in national unity and global solidarity to control COVID-19. No country will be safe until we are all safe&#8221; (<xref rid="bib0250" ref-type="bibr">Shields and Burger, 2020</xref>).</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0395">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Couch</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Hum. Vaccines Immunother.</source><volume>12</volume><year>2016</year><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id><pub-id pub-id-type="pmid">27269431</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vodovotz</surname><given-names>Y.</given-names></name></person-group><article-title>In silico augmentation of the drug development pipeline: examples from the study of acute inflammation</article-title><source>Drug Dev. Res.</source><volume>72</volume><year>2011</year><fpage>187</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1002/ddr.20415</pub-id><pub-id pub-id-type="pmid">21552346</pub-id><pub-id pub-id-type="pmcid">PMC3086282</pub-id></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>McGettigan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khetan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Segall</surname><given-names>N.</given-names></name><name name-style="western"><surname>Solis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brosz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fierro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marovich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Polakowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ledgerwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pajon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Knightly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leav</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivarsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Bahrami</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Payandeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zakeri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandehpour</surname><given-names>M.</given-names></name></person-group><article-title>Immunoinformatics: <italic toggle="yes">in silico</italic> approaches and computational design of a multi-epitope, immunogenic protein</article-title><source>Int. Rev. Immunol.</source><volume>38</volume><issue>6</issue><year>2019</year><fpage>307</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1080/08830185.2019.1657426</pub-id><pub-id pub-id-type="pmid">31478759</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Bartsch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name><name name-style="western"><surname>McKinnell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.Y.</given-names></name></person-group><article-title>Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention</article-title><source>Am. J. Prev. Med.</source><volume>59</volume><issue>4</issue><year>2020</year><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2020.06.011</pub-id><pub-id pub-id-type="pmid">32778354</pub-id><pub-id pub-id-type="pmcid">PMC7361120</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Long</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Totura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>J. Virol.</source><volume>85</volume><year>2011</year><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1128/jvi.06048-11</pub-id><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>The race for Coronavirus vaccines</article-title><source>Nature</source><volume>580</volume><year>2020</year><fpage>576</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">32346146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-01221-y</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41577-020-0308-3</pub-id><pub-id pub-id-type="pmcid">PMC7143200</pub-id><pub-id pub-id-type="pmid">32273594</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Carusi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burrage</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>B.</given-names></name></person-group><article-title>Bridging experiments, models and simulations: an integrative approach to validation in computational cardiac electrophysiology</article-title><source>Am. J. Physiol. - Hear. Circ. Physiol.</source><year>2012</year><pub-id pub-id-type="doi">10.1152/ajpheart.01151.2011</pub-id><pub-id pub-id-type="pmid">22582088</pub-id></element-citation></ref><ref id="bib0050"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Chukwudozie</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Chukwuanukwu</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Iroanya</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Eze</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Duru</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Dele-Alimi</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Kehinde</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Bankole</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Obi</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Okinedo</surname><given-names>E.U.</given-names></name></person-group><article-title>Attenuated subcomponent vaccine design targeting the SARS-CoV-2 nucleocapsid phosphoprotein RNA binding domain: in silico analysis</article-title><source>J. Immunol. Res.</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1155/2020/2837670</pub-id><pub-id pub-id-type="pmcid">PMC7501546</pub-id><pub-id pub-id-type="pmid">32964056</pub-id></element-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Chukwudozie</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Duru</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Ndiribe</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Aborode</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Oyebanji</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Emikpe</surname><given-names>B.O.</given-names></name></person-group><article-title>The relevance of bioinformatics applications in the discovery of vaccine candidates and potential drugs for COVID-19 treatment</article-title><source>Bioinform. Biol. Insights</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">11779322211002168</object-id><pub-id pub-id-type="doi">10.1177/11779322211002168</pub-id><pub-id pub-id-type="pmcid">PMC7968009</pub-id><pub-id pub-id-type="pmid">33795932</pub-id></element-citation></ref><ref id="bib0060"><mixed-citation publication-type="other" id="oref0060">COVID-19 Vaccine Tracker, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid19.trackvaccines.org/" id="intr0005">https://covid19.trackvaccines.org/</ext-link> (Accessed 27 March 2021).</mixed-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Crooke</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Poland</surname><given-names>G.A.</given-names></name></person-group><article-title>Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome</article-title><source>Sci. Rep.</source><volume>10</volume><issue>1</issue><year>2020</year><object-id pub-id-type="publisher-id">14179</object-id><pub-id pub-id-type="doi">10.1038/s41598-020-70864-8</pub-id><pub-id pub-id-type="pmcid">PMC7447814</pub-id><pub-id pub-id-type="pmid">32843695</pub-id></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>De Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmcid">PMC7097822</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Delany</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for the 21st century</article-title><source>EMBO Mol. Med.</source><volume>6</volume><issue>6</issue><year>2014</year><fpage>708</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1002/emmm.201403876</pub-id><pub-id pub-id-type="pmid">24803000</pub-id><pub-id pub-id-type="pmcid">PMC4203350</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar Rai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Redkar</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Gillurkar</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kushwaha</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guleria</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ella</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>B.</given-names></name></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id><pub-id pub-id-type="pmid">33485468</pub-id></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>P.L.</given-names></name></person-group><article-title>Cancer immunoprevention</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.coi.2016.01.002</pub-id><pub-id pub-id-type="pmcid">PMC4805487</pub-id><pub-id pub-id-type="pmid">26799207</pub-id></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Funk</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Laferri&#232;re</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ardakani</surname><given-names>A.</given-names></name></person-group><article-title>A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic</article-title><source>Front. Pharmacol.</source><year>2020</year><pub-id pub-id-type="doi">10.3389/fphar.2020.00937</pub-id><pub-id pub-id-type="pmcid">PMC7317023</pub-id><pub-id pub-id-type="pmid">32636754</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>J.C.C.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Finkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tokuyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schaefer-Babajew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Cipolla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Viant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Bram</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Breton</surname><given-names>G.</given-names></name><name name-style="western"><surname>H&#228;ggl&#246;f</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turroja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Millard</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weisblum</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tankelevich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Delgado</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dizon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unson-O&#8217;Brien</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shimeliovich</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robbiani</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gazumyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Hatziioannou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bjorkman</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bieniasz</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Caskey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>M.C.</given-names></name></person-group><article-title>Evolution of antibody immunity to SARS-CoV-2</article-title><source>Nature</source><year>2021</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03207-w</pub-id><pub-id pub-id-type="pmcid">PMC8221082</pub-id><pub-id pub-id-type="pmid">33461210</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Gouglas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thanh Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaloudis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Danielsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hammersland</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>R&#248;ttingen</surname><given-names>J.A.</given-names></name></person-group><article-title>Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study</article-title><source>Lancet Glob. Heal.</source><volume>6</volume><year>2018</year><fpage>e1386</fpage><lpage>e1396</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(18)30346-2</pub-id><pub-id pub-id-type="pmcid">PMC7164811</pub-id><pub-id pub-id-type="pmid">30342925</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Greaney</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Loes</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>J.D.</given-names></name></person-group><article-title>Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies</article-title><source>bioRxiv 2020</source><volume>12</volume><year>2021</year><pub-id pub-id-type="doi">10.1101/2020.12.31.425021</pub-id><comment>31.425021</comment><pub-id pub-id-type="pmcid">PMC7869748</pub-id><pub-id pub-id-type="pmid">33592168</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jadi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Marrama</surname><given-names>D.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.M. De</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>J.A.</given-names></name></person-group><article-title>Targets of t cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals ll article targets of t cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name></person-group><article-title>Databases and in silico tools for vaccine design</article-title><source>Methods mol. Biol. (Clifton, N.J.)</source><volume>993</volume><year>2013</year><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-342-8_8</pub-id><pub-id pub-id-type="pmcid">PMC12060024</pub-id><pub-id pub-id-type="pmid">23568467</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mansatta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V.</given-names></name><name name-style="western"><surname>Emary</surname><given-names>K.R.W.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name></person-group><article-title>What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2</article-title><source>Lancet Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30773-8</pub-id><pub-id pub-id-type="pmcid">PMC7837315</pub-id><pub-id pub-id-type="pmid">33125914</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lichty</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Pacis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzelepis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pernet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dumaine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grenier</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Mailhot-L&#233;onard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>E.</given-names></name><name name-style="western"><surname>Belle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Besla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mazer</surname><given-names>B.</given-names></name><name name-style="western"><surname>King</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Nijnik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name></person-group><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><volume>172</volume><issue>1-2</issue><year>2018</year><fpage>176</fpage><lpage>190.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="bib0135"><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name name-style="western"><surname>Lafuente</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reche</surname><given-names>P.</given-names></name></person-group><article-title>Prediction of MHC-Peptide binding: a systematic and comprehensive overview</article-title><source>Curr. Pharm. Des.</source><volume>15</volume><year>2009</year><fpage>3209</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.2174/138161209789105162</pub-id><pub-id pub-id-type="pmid">19860671</pub-id></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H.</given-names></name></person-group><article-title>Could mixing COVID vaccines boost immune response?</article-title><source>Nature</source><year>2021</year><pub-id pub-id-type="doi">10.1038/d41586-021-00315-5</pub-id><pub-id pub-id-type="pmid">33547431</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lubenets</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Botikov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Izhaeva</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ozharovskaya</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Esmagambetov</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Favorskaya</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Zrelkin</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Voronina</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Shcherbinin</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Semikhin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Simakova</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Tokarskaya</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Egorova</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Shmarov</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nikitenko</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Gushchin</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Smolyarchuk</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zyryanov</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Naroditsky</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Gintsburg</surname><given-names>A.L.</given-names></name></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id><pub-id pub-id-type="pmid">33545094</pub-id></element-citation></ref><ref id="bib0150"><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J.</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/nejmp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shahjin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Das</surname><given-names>Srijanee</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelmoaty</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Oleynikov</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yeapuri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mukadam</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saksena</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Herskovitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oupicky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Das</surname><given-names>Suvarthi</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Hettie</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Kevadiya</surname><given-names>B.D.</given-names></name></person-group><article-title>Nanocarrier vaccines for SARS-CoV-2</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.002</pub-id><pub-id pub-id-type="pmcid">PMC7794055</pub-id><pub-id pub-id-type="pmid">33428995</pub-id></element-citation></ref><ref id="bib0160"><element-citation publication-type="book" id="sbref0160"><person-group person-group-type="author"><name name-style="western"><surname>Mar&#237;a</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Arturo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Alicia</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Paulina</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gerardo</surname><given-names>A.O.</given-names></name></person-group><part-title>The impact of bioinformatics on vaccine design and development</part-title><source>Vaccines</source><year>2017</year><publisher-name>InTech</publisher-name><pub-id pub-id-type="doi">10.5772/intechopen.69273</pub-id></element-citation></ref><ref id="bib0165"><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name name-style="western"><surname>Mercurio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tragni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Busto</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies</article-title><source>Cell. Mol. Life Sci.</source><volume>78</volume><year>2021</year><fpage>1501</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03580-1</pub-id><pub-id pub-id-type="pmid">32623480</pub-id><pub-id pub-id-type="pmcid">PMC7334636</pub-id></element-citation></ref><ref id="bib0170"><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Andr&#233;s</surname><given-names>Jorge</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>Meer</surname><given-names>J.W.Mvander</given-names></name><name name-style="western"><surname>Mhlanga</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>W.J.M.</given-names></name><name name-style="western"><surname>Riksen</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Schlitzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schultze</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Benn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Andr&#233;s</surname><given-names>J.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>van de Veerdonk</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Bonten</surname><given-names>M.</given-names></name></person-group><article-title>Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection</article-title><source>Cell</source><volume>181</volume><issue>5</issue><year>2020</year><fpage>969</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.042</pub-id><pub-id pub-id-type="pmid">32437659</pub-id><pub-id pub-id-type="pmcid">PMC7196902</pub-id></element-citation></ref><ref id="bib0180"><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Scobie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadler</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blain</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>McClung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Campos-Outcalt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Mbaeyi</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacNeil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Keipp Talbot</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Dooling</surname><given-names>K.</given-names></name></person-group><article-title>Morbidity and mortality weekly report the advisory committee on immunization practices&#8217; interim recommendation for use of Janssen COVID-19 vaccine-united states, February 2021</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><volume>70</volume><issue>9</issue><year>2021</year><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7009e4</pub-id><pub-id pub-id-type="pmid">33661860</pub-id><pub-id pub-id-type="pmcid">PMC7948932</pub-id></element-citation></ref><ref id="bib0185"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name name-style="western"><surname>Pappalardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pennisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Castiglione</surname><given-names>F.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine protocols optimization: in silico experiences</article-title><source>Biotechnol. Adv.</source><year>2010</year><pub-id pub-id-type="doi">10.1016/j.biotechadv.2009.10.001</pub-id><pub-id pub-id-type="pmid">19833190</pub-id></element-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name name-style="western"><surname>Pappalardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Flower</surname><given-names>D.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pennisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>S.</given-names></name></person-group><article-title>Computational modelling approaches to vaccinology</article-title><source>Pharmacol. Res.</source><year>2015</year><pub-id pub-id-type="doi">10.1016/j.phrs.2014.08.006</pub-id><pub-id pub-id-type="pmid">25224605</pub-id></element-citation></ref><ref id="bib0195"><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name name-style="western"><surname>Pappalardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fichera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paparone</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lombardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pennisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pedretti</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Fiore</surname><given-names>F.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>S.</given-names></name></person-group><article-title>A computational model to predict the immune system activation by citrus-derived vaccine adjuvants</article-title><source>Bioinformatics</source><volume>32</volume><year>2016</year><fpage>2672</fpage><lpage>2680</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw293</pub-id><pub-id pub-id-type="pmid">27162187</pub-id></element-citation></ref><ref id="bib0200"><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name name-style="western"><surname>Pappalardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tshinanu</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Viceconti</surname><given-names>M.</given-names></name></person-group><article-title>In silico clinical trials: concepts and early adoptions</article-title><source>Brief. Bioinformatics</source><volume>20</volume><issue>5</issue><year>2019</year><fpage>1699</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1093/bib/bby043</pub-id><pub-id pub-id-type="pmid">29868882</pub-id></element-citation></ref><ref id="bib0205"><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Non-viral COVID-19 vaccine delivery systems</article-title><source>Adv. Drug Deliv. Rev.</source><volume>169</volume><year>2021</year><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.12.008</pub-id><pub-id pub-id-type="pmid">33340620</pub-id><pub-id pub-id-type="pmcid">PMC7744276</pub-id></element-citation></ref><ref id="bib0210"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koury</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Hammitt</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>Nell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#220;nal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tresnan</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Mather</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>&#350;ahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W.C.</given-names></name></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bib0215"><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name name-style="western"><surname>Prompetchara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ketloy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palaga</surname><given-names>T.</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic</article-title><source>Asian Pacific J. Allergy Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.12932/AP-200220-0772</pub-id><pub-id pub-id-type="pmid">32105090</pub-id></element-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name name-style="western"><surname>Quinlan</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parcells</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name></person-group><article-title>The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement</article-title><source>bioRxiv.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.10.036418</pub-id></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B.</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front. Immunol.</source><year>2018</year><pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmcid">PMC6156540</pub-id><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="book" id="sbref0230"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ortiz-Ospina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beltekian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hasell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>B.</given-names></name><name name-style="western"><surname>Giattino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roser</surname><given-names>M.</given-names></name></person-group><part-title>Coronavirus (COVID-19) Vaccinations</part-title><comment>Our World in Data. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ourworldindata.org/covid-vaccinations" id="intr0010">https://ourworldindata.org/covid-vaccinations</ext-link> (Accessed 03 February 2021)</comment><year>2021</year></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name name-style="western"><surname>Roncati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nasillo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lusenti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Riva</surname><given-names>G.</given-names></name></person-group><article-title>Signals of Th2 immune response from COVID-19 patients requiring intensive care</article-title><source>Ann. Hematol.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00277-020-04066-7</pub-id><pub-id pub-id-type="pmcid">PMC7205481</pub-id><pub-id pub-id-type="pmid">32382776</pub-id></element-citation></ref><ref id="bib0240"><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name name-style="western"><surname>Roper</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>K.E.</given-names></name></person-group><article-title>SARS vaccines: where are we? Expert Rev</article-title><source>Vaccines</source><year>2009</year><pub-id pub-id-type="doi">10.1586/erv.09.43</pub-id><pub-id pub-id-type="pmcid">PMC7105754</pub-id><pub-id pub-id-type="pmid">19538115</pub-id></element-citation></ref><ref id="bib0245"><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pennisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fichera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raciti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Viceconti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pappalardo</surname><given-names>F.</given-names></name></person-group><article-title>In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform</article-title><source>BMC Bioinformatics</source><volume>21</volume><year>2020</year><fpage>527</fpage><pub-id pub-id-type="doi">10.1186/s12859-020-03872-0</pub-id><pub-id pub-id-type="pmid">33308153</pub-id><pub-id pub-id-type="pmcid">PMC7733700</pub-id></element-citation></ref><ref id="bib0250"><element-citation publication-type="book" id="sbref0250"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>L.</given-names></name></person-group><part-title>Global Recovery Could Be Faster If COVID Vaccine Made Available to All: WHO Chief. Reuters</part-title><year>2020</year><comment>(Accessed 03 February 2021)</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.reuters.com/article/us-health-coronavirus-who-idUSKCN25229K" id="intr0015">https://www.reuters.com/article/us-health-coronavirus-who-idUSKCN25229K</ext-link></element-citation></ref><ref id="bib0255"><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name name-style="western"><surname>Smatti</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Al Thani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name></person-group><article-title>Viral-induced enhanced disease illness</article-title><source>Front. Microbiol.</source><volume>9</volume><year>2018</year><fpage>2991</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02991</pub-id><pub-id pub-id-type="pmid">30568643</pub-id><pub-id pub-id-type="pmcid">PMC6290032</pub-id></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><year>2019</year><pub-id pub-id-type="doi">10.3390/v11010059</pub-id><pub-id pub-id-type="pmcid">PMC6357155</pub-id><pub-id pub-id-type="pmid">30646565</pub-id></element-citation></ref><ref id="bib0265"><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name name-style="western"><surname>Strizova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Smetanova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bartunkova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Milota</surname><given-names>T.</given-names></name></person-group><article-title>Principles and challenges in anti-COVID-19 vaccine development</article-title><source>Int. Arch. Allergy Immunol.</source><year>2021</year><pub-id pub-id-type="doi">10.1159/000514225</pub-id><pub-id pub-id-type="pmcid">PMC7900461</pub-id><pub-id pub-id-type="pmid">33524979</pub-id></element-citation></ref><ref id="bib0270"><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name name-style="western"><surname>Thanh Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Andreadakis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#243;mez Rom&#225;n</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tollefsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayhew</surname><given-names>S.</given-names></name></person-group><article-title>The COVID-19 vaccine development landscape</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><pub-id pub-id-type="pmid">32273591</pub-id></element-citation></ref><ref id="bib0275"><element-citation publication-type="book" id="sbref0275"><person-group person-group-type="author"><name name-style="western"><surname>Tribouley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tribouley-Duret</surname><given-names>J.</given-names></name><name name-style="western"><surname>Appriou</surname><given-names>M.</given-names></name></person-group><part-title>Effect of Bacillus callmette Guerin (BCG) on the Receptivity of Nude Mice to Schistosoma mansoni]</part-title><comment>undefined</comment><year>1978</year><pub-id pub-id-type="pmid">157204</pub-id></element-citation></ref><ref id="bib0280"><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Sbrana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Atmar</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Couch</surname><given-names>R.B.</given-names></name></person-group><article-title>Correction: immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><pub-id pub-id-type="doi">10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id><pub-id pub-id-type="pmid">22536382</pub-id></element-citation></ref><ref id="bib0285"><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S.S.</given-names></name></person-group><article-title>Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus</article-title><source>Immunobiology</source><volume>225</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/j.imbio.2020.151949</pub-id><pub-id pub-id-type="pmid">32444135</pub-id></element-citation></ref><ref id="bib0290"><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group><article-title>Developments in viral vector-based vaccines</article-title><source>Vaccines</source><volume>2</volume><issue>3</issue><year>2014</year><fpage>624</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></element-citation></ref><ref id="bib0295"><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.A.C.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Barnabas</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.E.</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Briner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cicconi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Colin-Jones</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Darton</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Dheda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>C.J.A.</given-names></name><name name-style="western"><surname>Emary</surname><given-names>K.R.W.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Faust</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>S.H.C.</given-names></name><name name-style="western"><surname>Izu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenkin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Joe</surname><given-names>C.C.D.</given-names></name><name name-style="western"><surname>Kerridge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kwatra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lawrie</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lelliott</surname><given-names>A.</given-names></name><name name-style="western"><surname>Libri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lillie</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>A.V.A.</given-names></name><name name-style="western"><surname>Milan</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mujadidi</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Nana</surname><given-names>A.</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Padayachee</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Pittella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plested</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Rhead</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwarzbold</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>R.</given-names></name><name name-style="western"><surname>Snape</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Sprinz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tarrant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>T&#246;r&#246;k</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Toshner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.P.J.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Villafana</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M.E.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.S.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Oxford COVID Vaccine Trial Group</surname></name></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><volume>397</volume><issue>10269</issue><year>2021</year><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="bib0300"><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J. Virol.</source><volume>94</volume><year>2019</year><pub-id pub-id-type="doi">10.1128/jvi.02015-19</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id><pub-id pub-id-type="pmid">31826992</pub-id></element-citation></ref><ref id="bib0305"><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.O.</given-names></name></person-group><article-title>The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation</article-title><source>AAPS PharmSciTech</source><volume>21</volume><year>2020</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id><pub-id pub-id-type="pmid">32761294</pub-id></element-citation></ref><ref id="bib0310"><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weisblum</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Finkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaefer-Babajew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cipolla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Abernathy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Huey-Tubman</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turroja</surname><given-names>M.</given-names></name><name name-style="western"><surname>West</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Millard</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>V.</given-names></name><etal/></person-group><article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title><source>Nature</source><volume>10</volume><year>2021</year><pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><comment>1038/s41586-021-03324-03326. Advance online publication</comment><pub-id pub-id-type="pmcid">PMC8503938</pub-id><pub-id pub-id-type="pmid">33567448</pub-id></element-citation></ref><ref id="bib0315"><mixed-citation publication-type="other" id="oref0315">WHO &#8211; World Health Organization, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/initiatives/act-accelerator" id="intr0020">https://www.who.int/initiatives/act-accelerator</ext-link> (Accessed 03 February 2021).</mixed-citation></ref><ref id="bib0320"><element-citation publication-type="book" id="sbref0320"><person-group person-group-type="author"><name name-style="western"><surname>World Tourism Organization</surname></name></person-group><part-title>Global and Regional Tourism Performance</part-title><year>2021</year><comment>(Accessed 03 February 2021)</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.unwto.org/global-and-regional-tourism-performance" id="intr0025">https://www.unwto.org/global-and-regional-tourism-performance</ext-link></element-citation></ref><ref id="bib0325"><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name name-style="western"><surname>Wout</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Poell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Furth</surname><given-names>R.</given-names></name></person-group><article-title>The role of BCG/PPD-Activated macrophages in resistance against systemic candidiasis in mice</article-title><source>Scand. J. Immunol.</source><volume>36</volume><year>1992</year><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.1992.tb03132.x</pub-id><pub-id pub-id-type="pmid">1439583</pub-id></element-citation></ref><ref id="bib0330"><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Hui</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Yunkai</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Huijuan</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Wei</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>You</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Xuqin</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Yongli</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Wenling</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Xiaoming</given-names></name></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><year>2021</year><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="bib0335"><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.12.20035048</pub-id><pub-id pub-id-type="pmcid">PMC7350507</pub-id><pub-id pub-id-type="pmid">32719810</pub-id></element-citation></ref><ref id="bib0340"><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Yaling</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Yuansheng</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><year>2020</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="bib0345"><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.02.20030189</pub-id><pub-id pub-id-type="pmcid">PMC7184337</pub-id><pub-id pub-id-type="pmid">32221519</pub-id></element-citation></ref><ref id="bib0350"><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.Sen</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgments</title><p id="par0400">This work was supported by the <funding-source id="gs0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100006181</institution-id><institution>Bahia State Research Support Foundation</institution></institution-wrap></funding-source>.</p></ack></back></article></pmc-articleset>